Albert Seymour
Amministratore Delegato presso Seamless Therapeutics
Patrimonio netto: 213 741 $ in data 31/05/2024
Posizioni attive di Albert Seymour
Società | Posizione | Inizio | Fine |
---|---|---|---|
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Direttore/Membro del Consiglio | - | - |
Seamless Therapeutics
Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Amministratore Delegato | 23/04/2024 | - |
Presidente | 23/04/2024 | - | |
Direttore Tecnico/Scientifico/R&S | - | 23/04/2024 |
Storia della carriera di Albert Seymour
Precedenti posizioni note di Albert Seymour
Società | Posizione | Inizio | Fine |
---|---|---|---|
Q32 BIO INC. | Direttore/Membro del Consiglio | 06/09/2022 | 17/11/2023 |
Amministratore Delegato | 06/09/2022 | 17/11/2023 | |
Direttore Tecnico/Scientifico/R&S | 01/04/2016 | 06/09/2022 | |
Presidente | 21/04/2022 | 17/11/2023 | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/01/2011 | 01/03/2016 |
Formazione di Albert Seymour
University of Pittsburgh | Doctorate Degree |
The Johns Hopkins University | Graduate Degree |
University of Delaware | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Italia | 2 |
Germania | 2 |
Posizioni
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Settori
Consumer Services | 4 |
Health Technology | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
Seamless Therapeutics
Seamless Therapeutics Packaged SoftwareTechnology Services Seamless Therapeutics is a German company that is changing the paradigm of gene editing by unlocking the full potential of recombinases. The company is based in Dresden, Germany. The company is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. | Technology Services |
- Borsa valori
- Insiders
- Albert Seymour
- Esperienza